External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Thematic (Sector/Industry)

<ul><li>Pharmaceuticals: We expect pharmaceutical companies under our coverage to deliver a subdued yet positive performance in Q2FY27, with aggregate revenue rising 7.0% YoY and 3.6% QoQ to Rs 40,903 Cr.</li><li>However, EBITDA is estimated to decline 10% YoY but rise 6.3% QoQ to Rs 8,308 Cr, while adjusted PAT is likely to decline 19.6% YoY but moderately rise by 4.2% sequentially to Rs 4,331 Cr.</li><li>According to IQVIA data, chronic care segments such as cardiovascular and antidiabetic treatments are sustaining their outperformance against the broader Indian Pharmaceutical Market. </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pharmaceuticals: We expect pharmaceutical companies under our coverage to deliver a subdued yet positive performance in Q2FY27, with aggregate revenue rising 7.0% YoY and 3.6% QoQ to Rs 40,903 Cr.However, EBITDA is estimated to decline 10% YoY but rise 6.3% QoQ to Rs 8,308 Cr, while adjusted PAT is likely to decline 19.6% YoY but moderately rise by 4.2% sequentially to Rs 4,331 Cr.According to IQVIA data, chronic care segments such as cardiovascular and antidiabetic treatments are sustaining their outperformance against the broader Indian Pharmaceutical Market. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pharma and Healthcare - Q2FY27E: Result Preview

Equity Bottom-Up

<ul><li>Robust Revenue Growth &amp; Resilient Margin Outlook: Fortis delivered strong operational performance in Q1FY27, with consolidated revenue rising 17.5% YoY to Rs 2,545 Cr, driven by 19% growth in hospital revenue to Rs 2,187 Cr.</li><li>Consolidated operating EBITDA (pre-ESOP) grew 15.8% YoY to Rs 568 Cr, with the EBITDA margin at 22.3%.</li><li>Despite the short-term impact of ESOP costs of ~Rs 40 Cr per quarter in FY27, management reiterated its long-term target of achieving a 25% EBITDA margin by FY28, inclusive of ESOP costs.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Robust Revenue Growth &amp; Resilient Margin Outlook: Fortis delivered strong operational performance in Q1FY27, with consolidated revenue rising 17.5% YoY to Rs 2,545 Cr, driven by 19% growth in hospital revenue to Rs 2,187 Cr.Consolidated operating EBITDA (pre-ESOP) grew 15.8% YoY to Rs 568 Cr, with the EBITDA margin at 22.3%.Despite the short-term impact of ESOP costs of ~Rs 40 Cr per quarter in FY27, management reiterated its long-term target of achieving a 25% EBITDA margin by FY28, inclusive of ESOP costs.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Fortis Healthcare Ltd - Strong Growth; Unit Turnarounds On Track

<ul><li>Strong Revenue Growth Led by Hospitals: Fortis delivered a strong operational quarter with 17.5% YoY growth in consolidated revenue to Rs 2,265 Cr, driven primarily by the hospital segment.</li><li>Hospital revenue stood at Rs 1,938 Cr (+19.4% YoY), while Agilus reported 7.2% YoY growth in net revenue to Rs 327 Cr.</li><li>Margin expansion was visible across both hospital and diagnostics segments on a YoY basis.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Strong Revenue Growth Led by Hospitals: Fortis delivered a strong operational quarter with 17.5% YoY growth in consolidated revenue to Rs 2,265 Cr, driven primarily by the hospital segment.Hospital revenue stood at Rs 1,938 Cr (+19.4% YoY), while Agilus reported 7.2% YoY growth in net revenue to Rs 327 Cr.Margin expansion was visible across both hospital and diagnostics segments on a YoY basis.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Fortis Healthcare Ltd - Healthy Core Performance; Expansion to Drive Next Leg

<ul><li>Strong Revenue Growth Driven by Hospitals Segment: The Fortis Hospitals segment posted revenue of Rs 2,331 Cr, up 17.3% YoY and 7.6% QoQ, driven by the Hospital segment, which has reported 19.3% YoY growth, along with moderate growth in the Diagnostic Arm. </li><li>Stable ARPOB and Occupancy: ARPOB stood at Rs 68,800, marking a 5.9% YoY increase, while occupancy rose to 71% (up 100 bps QoQ), supported by a 13% YoY growth in occupied bed days.</li><li>EBITDA margin expanded to 23.9%, up 200 bps YoY and 120 bps QoQ.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Strong Revenue Growth Driven by Hospitals Segment: The Fortis Hospitals segment posted revenue of Rs 2,331 Cr, up 17.3% YoY and 7.6% QoQ, driven by the Hospital segment, which has reported 19.3% YoY growth, along with moderate growth in the Diagnostic Arm. Stable ARPOB and Occupancy: ARPOB stood at Rs 68,800, marking a 5.9% YoY increase, while occupancy rose to 71% (up 100 bps QoQ), supported by a 13% YoY growth in occupied bed days.EBITDA margin expanded to 23.9%, up 200 bps YoY and 120 bps QoQ.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Fortis Healthcare Ltd - Strong Quarter with Margin Expansion

<ul><li>Pharmaceuticals: We expect pharmaceutical companies under our coverage to deliver a subdued performance in Q3FY26, with aggregate revenue rising 6% YoY but declining 3% QoQ to Rs 36,683 Cr.</li><li>EBITDA is estimated to decline 1% YoY and 9.4% QoQ to Rs 8,297 Cr, while adjusted PAT is likely to shrink 7.6% YoY and 13.9% sequentially to Rs 5,014 Cr.</li><li>Sector operating margins are expected to settle at ~22.4%, primarily impacted by the sharp earnings normalisation of the superprofitable drug gRevlimid.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Pharmaceuticals: We expect pharmaceutical companies under our coverage to deliver a subdued performance in Q3FY26, with aggregate revenue rising 6% YoY but declining 3% QoQ to Rs 36,683 Cr.EBITDA is estimated to decline 1% YoY and 9.4% QoQ to Rs 8,297 Cr, while adjusted PAT is likely to shrink 7.6% YoY and 13.9% sequentially to Rs 5,014 Cr.Sector operating margins are expected to settle at ~22.4%, primarily impacted by the sharp earnings normalisation of the superprofitable drug gRevlimid.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Q3FY26 Earnings Preview - Pharma and Healthcare

India

Fortis Healthcare Ltd. is a health care provider.  The Company operates multi- specialty hospitals, a boutique-style hospital, and various satellite and heart command centers.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Fortis Healthcare (FORH IN)

Pharma and Healthcare - Q2FY27E: Result Preview

We expect pharmaceutical companies under our coverage to deliver a subdued yet positive performance in Q2FY27, with aggregate revenue rising 7.0%...

Axis Direct

Fortis Healthcare Ltd - Strong Growth; Unit Turnarounds On Track

Fortis delivered strong operational performance in Q1FY27, with consolidated revenue rising 17.5% YoY to Rs 2,545 Cr, driven by 19% growth in...

Axis Direct

Fortis Healthcare Ltd - Healthy Core Performance; Expansion to Drive Next Leg

Fortis delivered a strong operational quarter with 17.5% YoY growth in consolidated revenue to Rs 2,265 Cr, driven primarily by the hospital segment.

Axis Direct

Fortis Healthcare Ltd - Strong Quarter with Margin Expansion

he Fortis Hospitals segment posted revenue of Rs 2,331 Cr, up 17.3% YoY and 7.6% QoQ, driven by the Hospital segment, which has reported 19.3% YoY...

Axis Direct

Q3FY26 Earnings Preview - Pharma and Healthcare

We expect pharmaceutical companies under our coverage to deliver a subdued performance in Q3FY26, with aggregate revenue rising 6% YoY but...

Axis Direct

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)